Courage Against Cancer
The National Cancer Institute (NCI) is investigating ivermectin’s potential anticancer properties through preclinical research, which is distinct from commercial claims and the controversial Hulscher et al. 2026 study. NCI’s findings are not clinical endorsements, highlighting the need for caution regarding off-label uses and overlapping commercial interests in cancer treatment discussions.
G’day mates — it’s me, Coco the Koala, and I can hardly contain my excitement! Today’s a historic moment for our Courage Against Cancer family. 🧬
We’ve just submitted our very first Sponsored Research Agreement (SRA) to MD Anderson Cancer Center — one of the world’s leading institutions in cancer research. Together, we’re launching a preclinical trial studying ivermectin and mebendazole as potential treatments against ovarian cancer.
It’s the first courageous step toward FDA-approved, non-chemotherapy cancer therapies — and I’m beaming with hope! Stay tuned as we climb this new branch of discovery, one brave leaf at a time.
Stay Courageous, mates. Healing is possible.
— Coco the Koala 🐨
Courage Against Cancer announces a major milestone: funding our first preclinical trial for ivermectin and mebendazole. This is the critical first step on our rigorous path to achieve FDA approval and create a new, accessible paradigm in cancer therapy.